141 results on '"Łuczkowska, Karolina"'
Search Results
2. In vitro and in vivo characterization of human serum albumin-based PEGylated nanoparticles for BDNF and NT3 codelivery
- Author
-
Dąbkowska, Maria, Stukan, Iga, Kosiorowska, Alicja, Szatanik, Alicja, Łuczkowska, Karolina, Machalińska, Anna, and Machaliński, Bogusław
- Published
- 2024
- Full Text
- View/download PDF
3. Epigenetic activation of antiviral sensors and effectors of interferon response pathways during SARS-CoV-2 infection
- Author
-
Bińkowski, Jan, Taryma-Leśniak, Olga, Łuczkowska, Karolina, Niedzwiedź, Anna, Lechowicz, Kacper, Strapagiel, Dominik, Jarczak, Justyna, Davalos, Veronica, Pujol, Aurora, Esteller, Manel, Kotfis, Katarzyna, Machaliński, Bogusław, Parczewski, Miłosz, and Wojdacz, Tomasz K.
- Published
- 2022
- Full Text
- View/download PDF
4. The Depth of the Molecular Response in Patients with Chronic Myeloid Leukemia Correlates with Changes in Humoral Immunity.
- Author
-
Janowski, Michał, Łuczkowska, Karolina, Gniot, Michał, Lewandowski, Krzysztof, Safranow, Krzysztof, Helbig, Grzegorz, Machaliński, Bogusław, and Paczkowska, Edyta
- Subjects
- *
CHRONIC myeloid leukemia , *HUMORAL immunity , *COMPLEMENT (Immunology) , *BLOOD proteins , *VASCULAR endothelial growth factors - Abstract
Background and Objectives: The effective treatment of chronic myeloid leukemia leads to the restoration of proper immune system function. We aimed to investigate fluctuations in circulating cytokines, angiogenic factors and complement components in patients with CML during the first year of treatment with TKI and correlate them with the degree of achieved molecular response. Material and Methods: We recruited 31 patients with newly diagnosed CML. Peripheral blood and bone marrow samples were obtained, and concentrations of serum proteins were measured using an immunology multiplex assay. Results: The study cohort was divided into two groups of optimal or non-optimal in accordance with the European Leukemia Net (ELN) guidelines. We found significantly higher concentrations of C1q, C4 and C5a in serum after 3 months of TKI treatment in patients who achieved optimal responses in the 6 months after diagnosis. The most alterations were observed during 12 months of therapy. Patients in the optimal response group were characterized by higher serum concentrations of TGF-β, EGF, VEGF, Angiopoietin 1, IFN-γ and IL-8. Conclusions: The later plasma concentrations of complement components were significantly increased in patients with optimal responses. The changes after 12 months of treatment were particularly significant. Similar changes in bone marrow samples were observed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Standardized astragalus extract for attenuation of the immunosuppression induced by strenuous physical exercise: randomized controlled trial
- Author
-
Latour, Ewa, Arlet, Jaroslaw, Latour, Emilia E., Juszkiewicz, Artur, Łuczkowska, Karolina, Marcinkiewicz, Anita, Basta, Piotr, Trzeciak, Jerzy, Machaliński, Bogusław, and Skarpańska-Stejnborn, Anna
- Published
- 2021
- Full Text
- View/download PDF
6. The role of the electrokinetic charge of neurotrophis-based nanocarriers: protein distribution, toxicity, and oxidative stress in in vitro setting
- Author
-
Dąbkowska, Maria, Ulańczyk, Zofia, Łuczkowska, Karolina, Rogińska, Dorota, Sobuś, Anna, Wasilewska, Monika, Olszewska, Maria, Jakubowska, Katarzyna, and Machaliński, Bogusław
- Published
- 2021
- Full Text
- View/download PDF
7. Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound
- Author
-
Łuczkowska, Karolina, Sokolowska, Katarzyna Ewa, Taryma-Lesniak, Olga, Pastuszak, Krzysztof, Supernat, Anna, Bybjerg-Grauholm, Jonas, Hansen, Lise Lotte, Paczkowska, Edyta, Wojdacz, Tomasz K., and Machaliński, Bogusław
- Published
- 2021
- Full Text
- View/download PDF
8. Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action.
- Author
-
Kulig, Piotr, Łuczkowska, Karolina, Bakinowska, Estera, Baumert, Bartłomiej, and Machaliński, Bogusław
- Subjects
- *
PROTEASE inhibitors , *PERIPHERAL neuropathy , *APOPTOSIS , *DRUG resistance , *BORTEZOMIB , *METHYLATION , *EPIGENOMICS , *PHARMACODYNAMICS - Abstract
Simple Summary: The implantation of proteasome inhibitors was a milestone in the treatment of multiple myeloma (MM). One such first-in-class molecule was bortezomib (BTZ). Its cytotoxic effects are exerted through proteasome inhibition and the subsequent accumulation of misfolded or otherwise defective proteins. In addition to its main mechanisms of action, BTZ elicits various epigenetic alterations within target cells which are part of its mechanism of action. Importantly, epigenetic changes also participate in mediating resistance to BTZ. Some epigenetic agents such as azacitidine act synergically with BTZ or have the potential to restore sensitivity to the drug in resistant malignant cells. In this paper, we reviewed the epigenetic aspects of BTZ molecular action with a particular emphasis on drug resistance mechanisms and potential clinical implications. Bortezomib (BTZ) is widely implemented in the treatment of multiple myeloma (MM). Its main mechanism of action is very well established. BTZ selectively and reversibly inhibits the 26S proteasome. More precisely, it interacts with the chymotryptic site of the 20S proteasome and therefore inhibits the degradation of proteins. This results in the intracellular accumulation of misfolded or otherwise defective proteins leading to growth inhibition and apoptosis. As well as interfering with the ubiquitin–proteasome complex, BTZ elicits various epigenetic alterations which contribute to its cytotoxic effects as well as to the development of BTZ resistance. In this review, we summarized the epigenetic alterations elicited by BTZ. We focused on modifications contributing to the mechanism of action, those mediating drug-resistance development, and epigenetic changes promoting the occurrence of peripheral neuropathy. In addition, there are therapeutic strategies which are specifically designed to target epigenetic changes. Herein, we also reviewed epigenetic agents which might enhance BTZ-related cytotoxicity or restore the sensitivity to BTZ of resistant clones. Finally, we highlighted putative future perspectives regarding the role of targeting epigenetic changes in patients exposed to BTZ. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib.
- Author
-
Łuczkowska, Karolina, Kulig, Piotr, Baumert, Bartłomiej, and Machaliński, Bogusław
- Abstract
Multiple myeloma (MM) is a plasma cell malignancy that, despite recent advances in therapy, continues to pose a major challenge to hematologists. Currently, different classes of drugs are applied to treat MM, among others, proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. Most of them participate in an interplay with the immune system, hijacking its effector functions and redirecting them to anti-MM activity. Therefore, adjuvant therapies boosting the immune system may be potentially beneficial in MM therapy. Vitamin D (VD) and vitamin K (VK) have multiple so called "non-classical" actions. They exhibit various anti-inflammatory and anti-cancer properties. In this paper, we investigated the influence of VD and VK on epigenetic alterations associated with the proliferative potential of MM cells and the development of BTZ resistance. Our results showed that the development of BTZ resistance is associated with a global decrease in DNA methylation. On the contrary, both control MM cells and BTZ-resistant MM cells exposed to VD alone and to the combination of VD and VK exhibit a global increase in methylation. In conclusion, VD and VK in vitro have the potential to induce epigenetic changes that reduce the proliferative potential of plasma cells and may at least partially prevent the development of resistance to BTZ. However, further ex vivo and in vivo studies are needed to confirm the results and introduce new supplementation recommendations as part of adjuvant therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Novel design of (PEG-ylated)PAMAM-based nanoparticles for sustained delivery of BDNF to neurotoxin-injured differentiated neuroblastoma cells
- Author
-
Dąbkowska, Maria, Łuczkowska, Karolina, Rogińska, Dorota, Sobuś, Anna, Wasilewska, Monika, Ulańczyk, Zofia, and Machaliński, Bogusław
- Published
- 2020
- Full Text
- View/download PDF
11. 5-Aza-2′-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential.
- Author
-
Łuczkowska, Karolina, Kulig, Piotr, Rusińska, Klaudia, Baumert, Bartłomiej, and Machaliński, Bogusław
- Subjects
- *
MULTIPLE myeloma , *METHYLATION , *PLASMA cells , *DNA methylation , *PROTEASOME inhibitors , *DNA methyltransferases - Abstract
Multiple myeloma (MM) is a plasma cell malignancy that accounts for 1% of all cancers and is the second-most-common hematological neoplasm. Bortezomib (BTZ) is a proteasome inhibitor widely implemented in the treatment of MM alone or in combination with other agents. The development of resistance to chemotherapy is one of the greatest challenges of modern oncology. Therefore, it is crucial to discover and implement new adjuvant therapies that can bypass therapeutic resistance. In this paper, we investigated the in vitro effect of methylation inhibitor 5-Aza-2′-deoxycytidine on the proliferative potential of MM cells and the development of resistance to BTZ. We demonstrate that alterations in the DNA methylation profile are associated with BTZ resistance. Moreover, the addition of methylation inhibitor 5-Aza-2′-deoxycytidine to BTZ-resistant MM cells led to a reduction in the proliferation of the BTZ-resistant phenotype, resulting in the restoration of sensitivity to BTZ. However, further in vitro and ex vivo studies are required before adjuvant therapy can be incorporated into existing treatment regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. VEGFR and DPP-IV as Markers of Severe COVID-19 and Predictors of ICU Admission.
- Author
-
Pius-Sadowska, Ewa, Kulig, Piotr, Niedźwiedź, Anna, Baumert, Bartłomiej, Łuczkowska, Karolina, Rogińska, Dorota, Sobuś, Anna, Ulańczyk, Zofia, Kawa, Miłosz, Paczkowska, Edyta, Parczewski, Miłosz, Machalińska, Anna, and Machaliński, Bogusław
- Subjects
COVID-19 ,CYTOKINE release syndrome ,BLOOD cells ,SARS-CoV-2 ,NITRIC oxide - Abstract
The pathophysiology of the severe course of COVID-19 is multifactorial and not entirely elucidated. However, it is well known that the hyperinflammatory response and cytokine storm are paramount events leading to further complications. In this paper, we investigated the vascular response in the pathophysiology of severe COVID-19 and aimed to identify novel biomarkers predictive of ICU admission. The study group consisted of 210 patients diagnosed with COVID-19 (age range: 18–93; mean ± SD: 57.78 ± 14.16), while the control group consisted of 80 healthy individuals. We assessed the plasma concentrations of various vascular factors using the Luminex technique. Then, we isolated RNA from blood mononuclear cells and performed a bioinformatics analysis investigating various processes related to vascular response, inflammation and angiogenesis. Our results confirmed that severe COVID-19 is associated with vWF/ADAMTS 13 imbalance. High plasma concentrations of VEGFR and low DPP-IV may be potential predictors of ICU admission. SARS-CoV-2 infection impairs angiogenesis, hinders the generation of nitric oxide, and thus impedes vasodilation. The hypercoagulable state develops mainly in the early stages of the disease, which may contribute to the well-established complications of COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. TFF3 as a Diagnostic Biomarker in Kidney Transplant Patients.
- Author
-
Rogulska, Karolina, Wojciechowska-Koszko, Iwona, Krasnodębska-Szponder, Barbara, Kwiatkowski, Paweł, Roszkowska, Paulina, Dołęgowska, Barbara, Łuczkowska, Karolina, Machaliński, Bogusław, and Kosik-Bogacka, Danuta
- Subjects
KIDNEYS ,KIDNEY transplantation ,TREFOIL factors ,CHRONOBIOLOGY ,GLOMERULAR filtration rate ,URINE ,BIOMARKERS - Abstract
Intestinal trefoil factor 3 (TFF3) is a protein secreted by many cell types, and its serum and urine levels vary in patients with kidney disease. Therefore, the present study aimed to determine the diagnostic value of TFF3 in allogeneic kidney transplant patients included in the one-year follow-up. To analyze the influence of the diagnostic method used, we studied the type of biological material and the time elapsed since renal transplantation on the parameter's value. The study also aimed to investigate the relationship between TFF3 levels and creatinine and estimated glomerular filtration rate (eGFR) values in the serum and urine of the patients studied. The study used blood and urine samples from adult patients (n = 19) 24–48 h, 6 months, and 12 months after kidney transplantation. We collected one-time blood and urine from healthy subjects (n = 5) without renal disease. We applied immunoenzymatic ELISA and xMap Luminex flow fluorimetry to determine TFF3 in serum and urine. There was a significant difference in TFF3 levels in the serum of patients collected on the first one or two days after kidney transplantation compared to the control group (determined by ELISA and Luminex) and six months and one year after kidney transplantation (ELISA). We observed a correlation between creatinine concentration and urinary TFF3 concentration (ELISA and Luminex) and a negative association between eGFR and urinary (ELISA) and serum (Luminex) TFF3 concentration in patients on the first and second days after kidney transplantation. We noted significant correlations between eGFR and TFF3 levels in the serum and urine of patients determined by the two methods six months and one year after transplantation. In women, we observed that urinary TFF3 concentration increased significantly with increasing creatinine and that with increasing eGFR, urinary TFF3 concentration determined by two methods decreased significantly. In the present study, the choice of diagnostic method for the determination of TFF3 in serum and urine significantly affected the concentration of this biomarker. The values of this parameter determined by ELISA were higher than those assessed using the Luminex assay. Based on the presented results, we can conclude that TFF3 has great potential to monitor renal transplant patients. Determination of this protein in parallel with creatinine and eGFR levels in serum and urine may provide helpful diagnostic information. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Changes in the immune system in experimental acanthamoebiasis in immunocompetent and immunosuppressed hosts
- Author
-
Łanocha-Arendarczyk, Natalia, Kolasa-Wołosiuk, Agnieszka, Wojciechowska-Koszko, Iwona, Kot, Karolina, Roszkowska, Paulina, Krasnodębska-Szponder, Barbara, Paczkowska, Edyta, Machaliński, Bogusław, Łuczkowska, Karolina, Wiszniewska, Barbara, and Kosik-Bogacka, Danuta
- Published
- 2018
- Full Text
- View/download PDF
15. An attempt to induce an immunomodulatory effect in rowers with spirulina extract
- Author
-
Juszkiewicz, Artur, Basta, Piotr, Petriczko, Elżbieta, Machaliński, Bogusław, Trzeciak, Jerzy, Łuczkowska, Karolina, and Skarpańska-Stejnborn, Anna
- Published
- 2018
- Full Text
- View/download PDF
16. Complement Activation Products in Patients with Chronic Schizophrenia.
- Author
-
Rudkowski, Krzysztof, Waszczuk, Katarzyna, Tyburski, Ernest, Rek-Owodziń, Katarzyna, Plichta, Piotr, Podwalski, Piotr, Bielecki, Maksymilian, Mak, Monika, Michalczyk, Anna, Tarnowski, Maciej, Sielatycka, Katarzyna, Budkowska, Marta, Łuczkowska, Karolina, Dołęgowska, Barbara, Ratajczak, Mariusz Z., Samochowiec, Jerzy, Kucharska-Mazur, Jolanta, and Sagan, Leszek
- Subjects
COMPLEMENT activation ,PEOPLE with schizophrenia ,IMMUNE system ,CHRONICALLY ill ,DISEASE duration - Abstract
Evidence suggests a role of the immune system in the pathogenesis of a number of mental conditions, including schizophrenia (SCH). In terms of physiology, aside from its crucial protective function, the complement cascade (CC) is a critical element of the regeneration processes, including neurogenesis. Few studies have attempted to define the function of the CC components in SCH. To shed more light on this topic, we compared the levels of complement activation products (CAP) (C3a, C5a and C5b-9) in the peripheral blood of 62 patients with chronic SCH and disease duration of ≥ 10 years with 25 healthy controls matched for age, sex, BMI and smoking status. Concentrations of all the investigated CAP were elevated in SCH patients. However, after controlling for potential confounding factors, significant correlations were observed between SCH and C3a (M = 724.98 ng/mL) and C5a (M = 6.06 ng/mL) levels. In addition, multivariate logistic regression showed that C3a and C5b-9 were significant predictors of SCH. There were no significant correlations between any CAP and SCH symptom severity or general psychopathology in SCH patients. However, two significant links emerged between C3a and C5b-9 and global functioning. Increased levels of both complement activation products in the patient group as compared to healthy controls raise questions concerning the role of the CC in the etiology of SCH and further demonstrate dysregulation of the immune system in SCH patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Adiponectin, Leptin and Resistin in Patients with Psoriasis.
- Author
-
Słuczanowska-Głabowska, Sylwia, Staniszewska, Marzena, Marchlewicz, Mariola, Duchnik, Ewa, Łuczkowska, Karolina, Safranow, Krzysztof, Machaliński, Bogusław, and Pawlik, Andrzej
- Subjects
RESISTIN ,LEPTIN ,ADIPONECTIN ,PSORIASIS ,BODY surface area ,PSORIATIC arthritis - Abstract
Psoriasis is a common chronic, inflammatory skin disease characterised by keratinocyte hyperproliferation, parakeratosis, and T-cell infiltration. Adipose tissue has an endocrine function, producing an abundance of cytokines and adipokines. It has also been described that the major adipokines, leptin, resistin, and adiponectin, may be involved in the pathogenesis of psoriasis. The aim of the study was to examine the plasma levels of adiponectin, leptin, and resistin in patients with psoriasis and their correlations with disease activity parameters: Psoriasis Activity Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Body Surface Area (BSA) index, as well as selected clinical parameters. The study included 53 patients with the plaque type and 31 healthy controls. The plasma concentrations of adiponectin were significantly lower in patients with psoriasis (p < 0.001) than in the control group. The plasma concentrations of leptin were higher in patients with psoriasis, however, due to high intra-patient variability of leptin plasma concentrations these differences did not reach statistical significance (p = 0.2). The plasma concentrations of resistin were significantly increased in patients with psoriasis compared to healthy controls (p = 0.02). There were no statistically significant correlations between adiponectin and leptin plasma concentrations and values of PASI, DLQI, and BSA. The resistin plasma concentrations correlated significantly with DLQI values. Additionally, we examined the correlations between adiponectin, leptin, and resistin plasma concentrations, and selected clinical parameters. Plasma concentrations of adiponectin correlated significantly with CRP values and ALT values. Leptin plasma concentrations correlated significantly with creatinine values. The results of our study confirm the role of adiponectin, leptin, and resistin in the pathogenesis of psoriasis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Brain-derived neurotrophic factor: focus on the pathogenesis of multiple myeloma and the development of treatment-induced peripheral neuropathy.
- Author
-
Łuczkowska, Karolina, Kulig, Piotr, Baumert, Bartłomiej, and Machaliński, Bogusław
- Subjects
- *
BRAIN-derived neurotrophic factor , *MULTIPLE myeloma , *PERIPHERAL neuropathy , *CELL physiology , *DRUG resistance - Abstract
For many years, intensive research has been carried out on the in-depth understanding of the pathogenesis of multiple myeloma (MM). Nevertheless, the multifactorial nature of the disease, the development of drug resistance, and the side effects of therapy, make it difficult to effectively treat patients. One of the many factors involved in the pathogenesis of MM is brain-derived neurotrophic factor (BDNF). This factor is widely described as a neuroregenerative and neuroprotective agent, but it also regulates non-neuronal cell functions, such as proliferation, apoptosis, and viability. Therefore, BDNF appears to be a good therapeutic target in MM. On the other hand, its decreased concentration during treatment closely correlates with the development of peripheral neuropathy (PN). BDNF dualism requires a detailed understanding of its action on individual molecular mechanisms. Perhaps the optimization of the BDNF level will contribute to the improvement of MM treatment and the reduction of chemotherapy side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Apoptosis Evaluation in Circulating CD34+-Enriched Hematopoietic Stem and Progenitor Cells in Patients with Abnormally Increased Production of Endogenous Glucocorticoids in Course of Cushing's Syndrome.
- Author
-
Kawa, Miłosz P., Sobuś, Anna, Pius-Sadowska, Ewa, Łuczkowska, Karolina, Rogińska, Dorota, Wnęk, Szymon, Paczkowska, Edyta, Walczak, Mieczysław, Syrenicz, Anhelli, and Machaliński, Bogusław
- Subjects
HEMATOPOIETIC stem cells ,CUSHING'S syndrome ,CARDIOGENIC shock ,GLUCOCORTICOID receptors ,APOPTOSIS ,ENZYME-linked immunosorbent assay - Abstract
Abnormalities in hematological parameters of peripheral blood have been noted in patients with endogenous Cushing's Syndrome (CS) in the corticotropin (ACTH)-dependent and ACTH-independent forms. Nevertheless, the exact mechanism of glucocorticoids (GCs) action on human hematopoiesis is still not entirely clear. The aim of the study was to determine whether endogenous excessive production of GCs could affect apoptosis of CD34+ cells enriched in hematopoietic stem and progenitor cells (HSPCs) collected from the peripheral blood of newly diagnosed CS patients. Flow cytometry, Annexin-V enzyme-linked immunosorbent assay, TUNEL assay, real-time quantitative PCR, and microarray RNA/miRNA techniques were used to characterize CS patients' HSPCs. We found that the glucocorticoid receptor (GR) protein expression levels in CS were higher than in healthy controls. A complex analysis of apoptotic status of CS patients' HSPC cells showed that GCs significantly augmented apoptosis in peripheral blood-derived CD34+ cells and results obtained using different methods to detect early and late apoptosis in analyzed cell population were consistent. CS was also associated with significant upregulation in several members of the BCL-2 superfamily and other genes associated with apoptosis control. Furthermore, global gene expression analysis revealed significantly higher expression of genes associated with programmed cell death control in HSPCs from CS patients. These findings suggest that human endogenous GCs have a direct pro-apoptotic activity in hematopoietic CD34+ cells derived from CS subjects before treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. The Evidence That 25(OH)D3 and VK2 MK-7 Vitamins Influence the Proliferative Potential and Gene Expression Profiles of Multiple Myeloma Cells and the Development of Resistance to Bortezomib.
- Author
-
Łuczkowska, Karolina, Kulig, Piotr, Baumert, Bartłomiej, and Machaliński, Bogusław
- Abstract
Multiple myeloma (MM) remains an incurable hematological malignancy. Bortezomib (BTZ) is a proteasome inhibitor widely used in MM therapy whose potent activity is often hampered by the development of resistance. The immune system is vital in the pathophysiology of BTZ resistance. Vitamins D (VD) and K (VK) modulate the immune system; therefore, they are potentially beneficial in MM. The aim of the study was to evaluate the effect of BTZ therapy and VD and VK supplementation on the proliferation potential and gene expression profiles of MM cells in terms of the development of BTZ resistance. The U266 MM cell line was incubated three times with BTZ, VD and VK at different timepoints. Then, proliferation assays, RNA sequencing and bioinformatics analysis were performed. We showed BTZ resistance to be mediated by processes related to ATP metabolism and oxidative phosphorylation. The upregulation of genes from the SNORDs family suggests the involvement of epigenetic mechanisms. Supplementation with VD and VK reduced the proliferation of MM cells in both the non-BTZ-resistant and BTZ-resistant phenotypes. VD and VK, by restoring proper metabolism, may have overcome resistance to BTZ in vitro. This observation forms the basis for further clinical trials evaluating VD and VK as potential adjuvant therapies for MM patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways.
- Author
-
Janowski, Michał, Ulańczyk, Zofia, Łuczkowska, Karolina, Sobuś, Anna, Rogińska, Dorota, Pius-Sadowska, Ewa, Gniot, Michał, Kozłowski, Krzysztof, Lewandowski, Krzysztof, Helbig, Grzegorz, Machaliński, Bogusław, and Paczkowska, Edyta
- Subjects
PROTEIN-tyrosine kinase inhibitors ,CHRONIC myeloid leukemia ,T cell receptors ,BONE marrow cells ,MICROARRAY technology ,CHRONIC leukemia ,CD28 antigen - Abstract
Introduction: The aim of our research was to investigate changes in the molecular background of the immune response in the chronic phase (CP) of chronic myeloid leukaemia (CML) during treatment with tyrosine kinase inhibitors (TKIs). Methods: Global gene and miRNA expression profiles were assessed using genome-wide RNA and miRNA microarray technology in bone marrow mononuclear cells. Fifty-one patients were recruited, and bone marrow samples were taken at diagnosis before treatment with TKIs and after 3, 6, and 12 months of treatment with TKIs. The largest number of upregulated genes was observed when the 0-month group (time of diagnosis) was compared to the 3-month group; 1774 genes were significantly upregulated, and 390 genes were significantly downregulated. Discussion: Upregulated biological processes according to gene ontology (GO) classification involved basic cellular processes such as cell division, cell cycle, cell–cell adhesion, protein transport, mitotic nuclear division, apoptosis, and DNA replication. Differentially expressed miRNAs were annotated using GO classification to several immunity-related processes, including the T cell receptor signalling pathway, T cell costimulation, immune response, and inflammatory response. TKI therapy exerts a significant impact on cellular cycle processes and T-cell activation, which was proven at the molecular level. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 Course.
- Author
-
Pius-Sadowska, Ewa, Niedźwiedź, Anna, Kulig, Piotr, Baumert, Bartłomiej, Sobuś, Anna, Rogińska, Dorota, Łuczkowska, Karolina, Ulańczyk, Zofia, Wnęk, Szymon, Karolak, Igor, Paczkowska, Edyta, Kotfis, Katarzyna, Kawa, Miłosz, Stecewicz, Iwona, Zawodny, Piotr, and Machaliński, Bogusław
- Subjects
PROGNOSIS ,COVID-19 ,SEROCONVERSION ,COMPLEMENT (Immunology) ,COMPLEMENT activation ,CHEMOKINES ,CHEMOKINE receptors - Abstract
The exact pathophysiology of severe COVID-19 is not entirely elucidated, but it has been established that hyperinflammatory responses and cytokine storms play important roles. The aim of this study was to examine CMV status, select chemokines, and complement components in COVID-19, and how concentrations of given molecules differ over time at both molecular and proteomic levels. A total of 210 COVID-19 patients (50 ICU and 160 non-ICU patients) and 80 healthy controls were enrolled in this study. Concentrations of select chemokines (CXCL8, CXCL10, CCL2, CCL3, CCR1) and complement factors (C2, C9, CFD, C4BPA, C5AR1, CR1) were examined at mRNA and protein levels with regard to a COVID-19 course (ICU vs. non-ICU group) and CMV status at different time intervals. We detected several significant differences in chemokines and complement profiles between ICU and non-ICU groups. Pro-inflammatory chemokines and the complement system appeared to greatly contribute to the pathogenesis and development of severe COVID-19. Higher concentrations of CXCL8 and CCL2 in the plasma, with reduced mRNA expression presumably through negative feedback mechanisms, as well as CMV-positive status, correlated with more severe courses of COVID-19. Therefore, CXCL8, CCL2, and CMV seropositivity should be considered as new prognostic factors for severe COVID-19 courses. However, more in-depth research is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Plasma Levels of Interleukins 36α, 36β, and 37 in Patients with Psoriasis and Their Correlation with Disease Activity Parameters.
- Author
-
Słucznowska-Głabowska, Sylwia, Jaworska, Weronika, Staniszewska, Marzena, Tkacz, Marta, Safranow, Krzysztof, Łuczkowska, Karolina, Zagrodnik, Edyta, Stecewicz, Iwona, Machaliński, Bogusław, and Pawlik, Andrzej
- Subjects
INTERLEUKINS ,PSORIASIS ,BODY surface area ,INTERLEUKIN-37 ,SKIN diseases ,ROSACEA - Abstract
Psoriasis is a chronic, proliferative, inflammatory skin disease characterised by skin lesions and systemic symptoms. Numerous cytokines are produced in psoriasis as a result of inflammation. The aim of this study was to examine the plasma concentrations of IL-36α, IL-36β, and IL-37 in psoriasis and their correlations with disease activity parameters. This study recruited 84 individuals, 53 with plaque-type psoriasis and 31 healthy controls. The plaque type of psoriasis is the most common type and is typically characterized by circular-to-oval red plaques distributed over body surfaces of the extremities and scalp. In patients with psoriasis, we observed statistically significantly decreased plasma concentrations of IL-36β and IL-37. The concentrations of IL-36α were increased in comparison with control group. The plasma concentrations of IL-36α and IL-36β were statistically significantly correlated with all tested parameters of disease activity: the Psoriasis Activity Severity Index, Dermatology Life Quality Index, and Body Surface Area Index. There were no statistically significant correlations between plasma levels of IL-37 and the tested parameters of disease activity. These results indicate a role of IL36α, IL-36β, and IL-37 in the pathogenesis of psoriasis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Long-Term Treatment with Bortezomib Induces Specific Methylation Changes in Differentiated Neuronal Cells.
- Author
-
Łuczkowska, Karolina, Taryma-Leśniak, Olga, Bińkowski, Jan, Sokołowska, Katarzyna E., Strapagiel, Dominik, Jarczak, Justyna, Paczkowska, Edyta, Machaliński, Bogusław, and Wojdacz, Tomasz K.
- Subjects
- *
CELL differentiation , *NEURONS , *PERIPHERAL neuropathy , *TREATMENT duration , *BORTEZOMIB , *METHYLATION , *STEM cells , *DESCRIPTIVE statistics , *CELL lines , *MULTIPLE myeloma , *DATA analysis software , *EPIGENOMICS , *PHARMACODYNAMICS - Abstract
Simple Summary: We exposed LUHMES cells, differentiated into mature neurons, to bortezomib (BTZ) in two treatment cycles and analyzed the methylomes of these cells after each cycle, controlling the analysis for the methylation changes potentially induced by the long-term culture. Our results show that BTZ induces methylation changes that may affect cell morphogenesis, neurogenesis, and neurotransmission. These changes are specifically enriched within transcription factor binding sites of EBF, PAX, DLX, LHX, and HNF family members, which have been shown to regulate neurogenesis and neuronal differentiation. We further show that the observed methylation changes are not present in the SH-SY5Y cells that we used to study mechanisms of development of BTZ resistance. Altogether, our results show that BTZ treatment induces very specific changes in the methylomes of neuronal cells. Bortezomib (BTZ) is proteasome inhibitor, effectively used in the treatment of multiple myeloma, but frequently discontinued due to peripheral neuropathy, which develops in patients after consecutive treatment cycles. The molecular mechanisms affected by BTZ in neuronal cells, which result in neuropathy, remain unknown. However, BTZ is unlikely to lead to permanent morphological nerve damage, because neuropathy reverses after discontinuation of treatment, and nerve cells have very limited renewal capacity. We have previously shown that BTZ induces methylation changes in SH-SY5Y cells, which take part in the development of treatment resistance. Here, we hypothesized that BTZ affects the methylomes of mature neurons, and these changes are associated with BTZ neurotoxicity. Thus, we studied methylomes of neuronal cells, differentiated from the LUHMES cell line, after cycles of treatment with BTZ. Our results show that BTZ induces specific methylation changes in mature neurons, which are not present in SH-SY5Y cells after BTZ treatment. These changes appear to affect genes involved in morphogenesis, neurogenesis, and neurotransmission. Furthermore, identified methylation changes are significantly enriched within binding sites of transcription factors previously linked to neuron physiology, including EBF, PAX, DLX, LHX, and HNF family members. Altogether, our results indicate that methylation changes are likely to be involved in BTZ neurotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Adiponectin Is a Component of the Inflammatory Cascade in Rheumatoid Arthritis.
- Author
-
Łączna, Małgorzata, Kopytko, Patrycja, Tkacz, Marta, Zgutka, Katarzyna, Czerewaty, Michał, Tarnowski, Maciej, Larysz, Dariusz, Tkacz, Rafał, Kotrych, Daniel, Piotrowska, Katarzyna, Safranow, Krzysztof, Łuczkowska, Karolina, Machaliński, Bogusław, and Pawlik, Andrzej
- Abstract
Adiponectin is a secretory protein of adipocytes that plays an important role in pathological processes by participation in modulating the immune and inflammatory responses. The pro-inflammatory effect of adiponectin is observed in rheumatoid arthritis (RA). In this study, we examined adiponectin plasma levels and the expression of adiponectin in bone marrow tissue samples, synovium samples, and infrapatellar fat pad samples from patients with osteoarthritis (OA) and RA. Additionally we examined the expression of adiponectin receptors AdipoR1 and AdipoR2 in synovium samples and infrapatellar fat pad samples from patients with OA and RA. We also assessed the correlations between adiponectin plasma concentrations, adiponectin expression in bone marrow, synovium, infrapatellar fat pad, and plasma levels of selected cytokines. We found increased expression of adiponectin in synovium samples and infrapatellar fat pad samples from patients with RA as compared to patients with OA. There were no statistically significant differences of adiponectin plasma levels and adiponectin expression in bone marrow tissue samples between OA and RA patients. There were no differences in the expression of AdipoR1 and AdipoR2 at the mRNA level in synovial tissue and the infrapatellar fat pad between RA and OA patients. However, in immunohistochemical analysis in samples of the synovial membrane from RA patients, we observed very strong expression of adiponectin in intima cells, macrophages, and subintimal fibroblasts, such as synoviocytes, vs. strong expression in OA samples. Very strong expression of adiponectin was also noted in adipocytes of Hoffa's fat pad of RA patients. Expression of AdipoR1 was stronger in RA tissue samples, while AdipoR2 expression was very similar in both RA and OA samples. Our results showed increased adiponectin expression in the synovial membrane and Hoffa's pad in RA patients compared to that of OA patients. However, there were no differences in plasma adiponectin concentrations and its expression in bone marrow. The results suggest that adiponectin is a component of the inflammatory cascade that is present in RA. Pro-inflammatory factors enhance the expression of adiponectin, especially in joint tissues—the synovial membrane and Hoffa's fat pad. In turn, adiponectin also increases the expression of further pro-inflammatory mediators. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Psychopathology and Stem Cell Mobilization in Ultra-High Risk of Psychosis and First-Episode Psychosis Patients.
- Author
-
Waszczuk, Katarzyna, Kucharska-Mazur, Jolanta, Tyburski, Ernest, Rek-Owodziń, Katarzyna, Plichta, Piotr, Rudkowski, Krzysztof, Podwalski, Piotr, Grąźlewski, Tomasz, Mak, Monika, Misiak, Błażej, Michalczyk, Anna, Tarnowski, Maciej, Sielatycka, Katarzyna, Szczęśniak, Angelika, Łuczkowska, Karolina, Dołęgowska, Barbara, Budkowska, Marta, Ratajczak, Mariusz Z., and Samochowiec, Jerzy
- Published
- 2022
- Full Text
- View/download PDF
27. Vitamin D as a Potential Player in Immunologic Control over Multiple Myeloma Cells: Implications for Adjuvant Therapies.
- Author
-
Kulig, Piotr, Łuczkowska, Karolina, Bielikowicz, Anna, Zdrojewska, Debora, Baumert, Bartłomiej, and Machaliński, Bogusław
- Abstract
Multiple myeloma (MM) is a plasma cell malignancy with multifactorial etiology. One of the underlying mechanisms is immune system dysregulation. Immunotherapy is being widely introduced into various MM treatment protocols. Nevertheless, little is known about boosting the immune system with supportive treatment. Although classical actions of vitamin D (VD) are very well established, their non-classical actions related to the modulation of the immune system in MM are still a subject of ongoing research. In this literature review, we intend to summarize research conducted on VD and MM, both in vitro and in vivo, with particular emphasis on immune system modulation, the induction of the differentiation of malignant MM cells, synergic activity with anti-MM drugs, and MM-associated peripheral neuropathy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. microRNAs as the biomarkers of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma.
- Author
-
Łuczkowska, Karolina, Rogińska, Dorota, Ulańczyk, Zofia, Safranow, Krzysztof, Paczkowska, Edyta, Baumert, Bartłomiej, Milczarek, Sławomir, Osękowska, Bogumiła, Górska, Martyna, Borowiecka, Ewa, Sommerfeld, Krzysztof, Zawodny, Piotr, Szudy-Szczyrek, Aneta, Hus, Marek, and Machaliński, Bogusław
- Subjects
- *
MULTIPLE myeloma , *PERIPHERAL neuropathy , *MICROARRAY technology , *RECEIVER operating characteristic curves , *TREATMENT effectiveness - Abstract
Multiple myeloma (MM) is a malignant, incurable neoplastic disease. The currently used treatment significantly improves the prognosis and extends the survival time of patients. Unfortunately, a common side effect of the therapy is peripheral neuropathy, which may lead to dose reduction or complete treatment discontinuation/modification. In this study, we examined the changes in plasma levels of circulating miRNAs in myeloma patients to define potential factors characteristic for drug-induced peripheral neuropathy (DiPN). Global miRNA expression profile in the plasma of patients with MM during treatment was determined using miRNA microarray technology. Receiver operating characteristic (ROC) analysis allowed the identification of three miRNAs (miR-22-3p; miR-23a-3p; miR-24-3p) that could be a potential biomarker of PN. The most promising results were obtained for miR-22-3p, which was characterized by ROC area under curve (AUC) = 0.807. Our results suggest a relationship between the DiPN in patients with MM and the level of selected miRNAs in the plasma. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Peripheral neuropathy in patients with multiple myeloma: molecular effects of bortezomib.
- Author
-
Łuczkowska, Karolina and Machaliński, Bogusław
- Subjects
MULTIPLE myeloma treatment ,B cell tumors ,NEUROPATHY ,BORTEZOMIB ,ANTINEOPLASTIC agents - Abstract
Multiple myeloma (MM) is a B cell neoplasm characterized by uncontrolled growth of malignant plasma cells within the bone marrow. The introduction of new treatment regimens and medicinal substances, particularly proteasome inhibitors (e.g. bortezomib or carfilzomib) and immunomodulatory drugs (e.g. lenalidomide, pomalidomide, and monoclonal antibodies), have radically changed MM therapy by improving the response rate and progression-free survival. However, these potentially effective drugs are associated with a number of side effects, the most serious of which include peripheral neuropathy, which appears in 40% of MM patients with bortezomib treatment and up to 70% with thalidomide treatment during long-term exposure. Usually, symptoms of neuropathy disappear after drug discontinuation or dose reduction. However, as a result, the effectiveness of the treatment is lowered and survival time is reduced. The pathogenesis of chemotherapy-induced peripheral neuropathy is not fully understood. Current research focuses on areas such as the change in the expression of genes responsible for the proper functioning of the nervous system, neuroprotective protein factors, oxidative stress, pro-inflammatory factors and epigenetic changes (miRNA, DNA methylation or histone acetylation). Thoroughly elucidating the mechanisms responsible for the development of chemotherapy-induced peripheral neuropathy will allow us to reduce/eliminate this side effect and improve quality of life for patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Humoral Influence of Repeated Lineage-Negative Stem/Progenitor Cell Administration on Articulatory Functions in ALS Patients.
- Author
-
Sobuś, Anna, Baumert, Bartłomiej, Pawlukowska, Wioletta, Gołąb-Janowska, Monika, Paczkowska, Edyta, Wełnicka, Agnieszka, Meller, Agnieszka, Machowska-Sempruch, Karolina, Zawiślak, Alicja, Łuczkowska, Karolina, Milczarek, Sławomir, Osękowska, Bogumiła, Safranow, Krzysztof, Rotter, Iwona, Nowacki, Przemysław, and Machaliński, Bogusław
- Subjects
PROGENITOR cells ,AMYOTROPHIC lateral sclerosis ,DEGLUTITION ,SOFT palate ,CELLULAR therapy ,CEREBROSPINAL fluid ,NEURODEGENERATION ,BONES - Abstract
Amyotrophic lateral sclerosis (ALS) remains a fatal, neurodegenerative disease frequently leading to dysarthria and impaired swallowing. Better understanding of ALS pathophysiology is prompting the use of humoral cell therapies. Hence, a repeated cellular therapy was applied to ALS patients as an attempt to prevent speech deterioration. Autologous bone marrow-derived lineage-negative (Lin
− ) cells were intrathecally administered three times at six-week intervals to 42 sporadic ALS patients. Patients were examined for articulatory functions using subjective (VHI) and objective (FDA) scales. Selected trophic, proinflammatory factors and expression profiles of miRNA were measured in cerebrospinal fluid (CSF) and plasma by multiplex Luminex and q-PCR in different timepoints. Of the 42 patients who received the Lin− cells, 6 showed improvement in articulatory functions, 27 remained stable, and 9 deteriorated after 18 weeks of therapy according to FDA scale. Clinical improvement was particularly evident by the 7th day of each cell application and concerned better cough and swallow reflex, soft palate, laryngeal time, pitch, and volume. These results correlated with significant changes in the concentration of various trophic and proinflammatory factors and miRNA expression profiles. A multiple application of Lin− cells proved to be safe and feasible. The repeated procedure can potentate a humoral effect and prevent speech deterioration. A short-lasting trophic effect of each Lin− cells administration was observed on local and systemic level. However, further in-depth studies are necessary to sustain the beneficial effect. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
31. The Interplay Between Systemic Inflammatory Factors and MicroRNAs in Age-Related Macular Degeneration.
- Author
-
Litwińska, Zofia, Sobuś, Anna, Łuczkowska, Karolina, Grabowicz, Aleksandra, Mozolewska-Piotrowska, Katarzyna, Safranow, Krzysztof, Kawa, Miłosz Piotr, Machaliński, Bogusław, and Machalińska, Anna
- Subjects
RETINAL degeneration ,LYMPHOCYTE count ,VISUAL acuity ,BLOOD cells ,MULTIVARIATE analysis ,LOW vision - Abstract
We aimed to explore the expression of systemic inflammatory factors and selected intracellular miRNAs that regulate inflammatory signaling pathways potentially involved in age-related macular degeneration (AMD) pathogenesis. A total of 179 patients with wet AMD, 175 with dry AMD and 121 controls were enrolled in the study. Soluble inflammatory factors were analyzed in plasma samples using Luminex technology. Expression of selected miRNAs was analyzed in isolated nucleated peripheral blood cells (PBNCs) using real-time qPCR. Wet AMD was an independent factor associated with higher concentrations of IL-6 (β = +0.24, p = 0.0004), GM-CSF (β = +0.31, p < 0.001), IFN-γ (β = +0.58, p < 0.001), higher expression of miRNA-23a-3p (β = +0.60, p < 0.0001), miRNA-30b (β = +0.32, p < 0.0001), miRNA-191-5p (β = +0.28, p < 0.0001) and lower concentration of IL-1β (β = −0.25, p = 0.0003), IL-5 (β = −0.45, p < 0.001), IL-10 (β = −0.45, p < 0.001), IL-12 (β = −0.35, p < 0.001), lower expression of miRNA-16-5p (β = −0.31, p < 0.0001), miRNA-17-3p (β = −0.18, p = 0.01), miRNA-150-5p (β = −0.18, p = 0.01) and miRNA-155-5p (β = −0.47, p < 0.0001). Multivariate analysis revealed that dry AMD was an independent factor associated with higher concentration of GM-CSF (β = +0.34, p < 0.001), IL-6 (β = +0.13, p = 0.05), higher expression of miRNA-23a-3p (β = +0.60, p < 0.0001), miRNA-126-3p (β = +0.23, p = 0.0005), miRNA-126-5p (β = +0.16, p = 0.01), miRNA 146a (β = +0.14, p = 0.03), and mRNA191-5p (β = +0.15, p = 0.03) and lower concentrations of TNF-α (β = +0.24, p = 0.0004), IL-1β (β = −0.39, p < 0.001), IL-2 (β = −0.20, p = 0.003), IL-5 (β = −0.54, p < 0.001), IL-10 (β = −0.56, p < 0.001), IL-12 (β = −0.51, p < 0.001), lower expression of miRNA-16-5p (β = −0.23, p = 0.0004), miRNA-17-3p (β = −0.20, p = 0.003) and miRNA-17-5p (β = −0.19, p = 0.004). Negative correlations between visual acuity and WBC, lymphocyte count, TNF-α, IL-1 β, IL-2, IL-4, IL-6, IL-10 concentrations and miRNA-191-5p, as well as positive correlations between visual acuity and miRNA-126-3p, -126-5p, and -155-5p PBNCs expression were found in AMD patients. No such correlations were found in the control group. Our results may suggest the role of both intra- and extracellular mechanisms implicated in inflammatory response regulation in multifactorial AMD pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
32. Influence of Lineage-Negative Stem Cell Therapy on Articulatory Functions in ALS Patients.
- Author
-
Pawlukowska, Wioletta, Baumert, Bartłomiej, Gołąb-Janowska, Monika, Sobuś, Anna, Wełnicka, Agnieszka, Meller, Agnieszka, Machowska-Sempruch, Karolina, Zawiślak, Alicja, Łuczkowska, Karolina, Milczarek, Sławomir, Osękowska, Bogumiła, Paczkowska, Edyta, Rotter, Iwona, Nowacki, Przemysław, and Machaliński, Bogusław
- Subjects
STEM cell treatment ,AMYOTROPHIC lateral sclerosis ,TUMOR necrosis factor receptors ,BRAIN-derived neurotrophic factor ,ADULT respiratory distress syndrome ,SPINAL canal - Abstract
Introduction. Amyotrophic lateral sclerosis (ALS) is a fatal, neurodegenerative disease, leading to loss of muscle strength and motor control. Impaired speech and swallowing lower the quality of life and consequently may induce acute respiratory failure. Bone marrow-derived stem and progenitor cells (SPCs) may be a valuable source of trophic factors. In this study, we assessed whether adjuvant cellular therapy could affect the levels of selected neurotrophins and proinflammatory factors in the cerebrospinal fluid (CSF) and subsequently prevent the deterioration of articulation. Materials and Methods. The study group consisted of 32 patients with sporadic ALS who underwent autologous lineage-negative (Lin
− ) stem cell intrathecal administration to the spinal canal. Lin− cells were aspirated from the bone marrow and isolated using immunomagnetic beads and a lineage cell depletion kit. Patients were examined for articulatory functions by means of the Voice Handicap Index (VHI) questionnaire and Frenchay Dysarthria Assessment (FDA). In parallel, we carried out the analysis of selected trophic and proinflammatory factors in CSF utilizing multiplex fluorescent bead-based immunoassays. Results. Of the 32 patients who received the Lin− progenitor cell therapy, 6 (group I) showed improvement in articulatory functions, 23 remained stable (group II), and 3 deteriorated (group III) on the 28th day. The improvement was particularly noticeable in a better cough reflex, laryngeal time, and dribble reflex. A statistically significant lower level of brain-derived neurotrophic factor (BDNF) was observed on day 0 in group I compared to group II. The CSF concentrations of C-reactive protein (CRP) in group I significantly decreased 7 days after Lin− SPC transplantation. On the contrary, a significant increase in the tumor necrosis factor receptor (TNF-R) level was confirmed among patients from group I with improvement of dribble and coughing reflex, tongue movements, and respiration on the 7th day, as well as on day 28 including dribble reflex solely. Conclusions. An application of Lin− stem cells could potentate the beneficial humoral effect. The prevention of deterioration of articulatory functions in ALS patients after applying adjuvant Lin− stem cell therapy seems to be promising. Although the procedure is safe and feasible, it requires further in-depth studies. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
33. Extracellular vesicles in hematological malignancies.
- Author
-
Litwińska, Zofia, Łuczkowska, Karolina, and Machaliński, Bogusław
- Subjects
- *
HEMATOLOGIC malignancies , *BLOOD diseases - Abstract
Extracellular vesicles (EVs) act as transporters that carry regulatory molecules between cells in physiologic and pathologic states; therefore, they play a crucial role in thrombosis, inflammation, angiogenesis, vascular dysfunction and other processes that affect the course of hematologic diseases. Within the tumor microenvironment, for example the leukemic bone marrow, EVs-mediated signaling may direct the activities of surrounding cells and act as a positive feedback loop that contributes to cancer progression. The importance of EVs in hematological malignancies is also attributed to their involvement in development of multidrug resistance and the hypercoagulable state related to hematologic disorders, which may be partially influenced by an increase in the total number of EVs. In this review, we focused on the role of EVs in hematologic malignancies and in particular on their influence on the BM microenvironment, their role in angiogenesis and the possible use of EVs as biomarkers of disease progression and drug resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Plasma concentration of humoral factors in patients with chronic myeloid leukemia and early molecular response.
- Author
-
Janowski, Michał, Ulańczyk, Zofia, Łuczkowska, Karolina, Rogińska, Dorota, Sobuś, Anna, Pius-Sadowska, Ewa, Gniot, Michał, Lewandowski, Krzysztof, Helbig, Grzegorz, Paczkowska, Edyta, and Machaliński, Bogusław
- Subjects
CHRONIC myeloid leukemia ,DASATINIB ,COMPLEMENT activation ,VASCULAR endothelial growth factors ,PROGRESSION-free survival ,PROGNOSIS - Abstract
Introduction: Cellular component of innate immune system, represented by NK cells and T-cells seems to play pivotal role in controlling of residual leukemic cells in chronic myeloid leukemia (CML) in patients with treatment free remission. However, complement system, circulating cytokines and chemokines play important role in innate immune response. The result BCR-ABL/ABL ratio <10% at 3 months of treatment is determined as early molecular response (EMR). EMR is associated with positive long-term outcome in terms of overall survival and progression-free survival. The goal of our prospective "real life" study was to identify relevant EMR-related cytokines that may be candidates for future prognostic factors. Material and methods: In this study, we recruited 14 patients with newly diagnosed CML in chronic phase. Peripheral blood samples were obtained from patients at different time points: i) at diagnosis and ii) after 3 months of TKIs treatment. Plasma concentrations of cytokines (IFN-γ, interleukins, GM-CSF, TGF-β, TNF-α and TNF-β), immunoglobulins, complement proteins, matrix metalloproteinases and angiogenic factors were assessed by xMAP beadbased technology (Luminex). We divided study cohort into two groups according to the response obtained, i) EMR, and ii) non-EMR. Results: We observed at 3-month, significantly lower concentrations of platelet-derived growth factor-BB human (PDGF-BB), C-C motif chemokine ligand 5 (CCL5), Angiopoietin-1 and TIMP metallopeptidase inhibitor 1 (TIMP1) in EMR group compared to non-EMR. Conclusions: We found that achieving the EMR was associated with lower concentrations of PDGF-BB, CCL5, Angio-1, and TIMP1 in our patients. Cytokines such PDGF, CCL5, Angio-1, TIMP1 may contribute in leukemogenesis and may play negative role in CML because of their pro-proliferative, angiogenic and pro-inflammatory effects. These findings suggest the importance of further research of these simple measurements in risk stratification in patients with CML. [ABSTRACT FROM AUTHOR]
- Published
- 2022
35. Depletion of the Third Complement Component Ameliorates Age-Dependent Oxidative Stress and Positively Modulates Autophagic Activity in Aged Retinas in a Mouse Model.
- Author
-
Rogińska, Dorota, Kawa, Miłosz P., Pius-Sadowska, Ewa, Lejkowska, Renata, Łuczkowska, Karolina, Wiszniewska, Barbara, Kaarniranta, Kai, Paterno, Jussi J., Schmidt, Christian A., Machaliński, Bogusław, and Machalińska, Anna
- Published
- 2017
- Full Text
- View/download PDF
36. The Impact of Growth Hormone Therapy on the Apoptosis Assessment in CD34+ Hematopoietic Cells from Children with Growth Hormone Deficiency.
- Author
-
Kawa, Miłosz Piotr, Stecewicz, Iwona, Piecyk, Katarzyna, Paczkowska, Edyta, Roginska, Dorota, Sobus, Anna, Łuczkowska, Karolina, Pius-Sadowska, Ewa, Gawrych, Elzbieta, Petriczko, Elzbieta, Walczak, Mieczysław, and Machalinski, Bogusław
- Subjects
SOMATOTROPIN ,PROGENITOR cells ,GENE expression ,CELL cycle ,APOPTOSIS - Abstract
Growth hormone (GH) modulates hematopoietic cell homeostasis and is associated with apoptosis control, but with limited mechanistic insights. Aim of the study was to determine whether GH therapeutic supplementation (GH-TS) could affect apoptosis of CD34+ cells enriched in hematopoietic progenitor cells of GH deficient (GHD) children. CD34+ cells from peripheral blood of 40 GHD children were collected before and in 3rd and 6th month of GH-TS and compared to 60 controls adjusted for bone age, sex, and pubertal development. Next, apoptosis assessment via different molecular techniques was performed. Finally, to comprehensively characterize apoptosis process, global gene expression profile was determined using genome-wide RNA microarray technology. Results showed that GH-TS significantly reduced spontaneous apoptosis in CD34+ cells (p < 0.01) and results obtained using different methods to detect early and late apoptosis in analyzed cells population were consistent. GH-TS was also associated with significant downregulation of several members of TNF-alpha superfamily and other genes associated with apoptosis and stress response. Moreover, the significant overexpression of cyto-protective and cell cycle-associated genes was detected. These findings suggest that recombinant human GH has a direct anti-apoptotic activity in hematopoietic CD34+ cells derived from GHD subjects in course of GH-TS. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
37. The influence of BDNF on human umbilical cord blood stem/ progenitor cells: Implications for stem cell-based therapy of neurodegenerative disorders.
- Author
-
Paczkowska, Edyta, Łuczkowska, Karolina, Piecyk, Katarzyna, Rogińska, Dorota, Pius-Sadowska, Ewa, Ustianowski, Przemysław, Cecerska, Elżbieta, DołŽgowska, Barbara, Celewicz, Zbigniew, and Machaliński, Bogusław
- Published
- 2015
- Full Text
- View/download PDF
38. Bortezomib-Induced Epigenetic Alterations in Nerve Cells: Focus on the Mechanisms Contributing to the Peripheral Neuropathy Development.
- Author
-
Łuczkowska, Karolina, Rogińska, Dorota, Kulig, Piotr, Bielikowicz, Anna, Baumert, Bartłomiej, and Machaliński, Bogusław
- Subjects
- *
PERIPHERAL neuropathy , *NEURONS , *EPIGENETICS , *HISTONE acetylation , *NEURONAL differentiation , *WNT signal transduction - Abstract
Bortezomib-induced peripheral neuropathy (BiPN) occurs in approximately 40% of patients with multiple myeloma. The induction of severe neuropathy entails the dose reduction or complete elimination of bortezomib (BTZ). Interestingly, discontinuation of BTZ mostly results in a reduction or complete resolution of peripheral neuropathy (PN) symptoms. Therefore, it is likely that the BiPN mechanisms are based on temporary/reversible changes such as epigenetic alterations. In this study, we examined the effect of treating nerve cells, differentiated from the Lund human mesencephalic (dLUHMES) cell line, with several low-dose BTZ (0.15 nM) applications. We showed a significant decrease in global histone H3 acetylation as well as histone H3 lysine 9 acetylation. Moreover, analysis of the genetic microarray showed changes mainly in epigenetic processes related to chromatin rearrangement, chromatin silencing, and gene silencing. GSEA analysis revealed three interesting signaling pathways (SIRT1, B-WICH and, b-Catenin) that may play a pivotal role in PN development. We also performed an analysis of the miRNA microarray which showed the interactions of miR-6810-5p with the genes MSN, FOXM1, TSPAN9, and SLC1A5, which are directly involved in neuroprotective processes, neuronal differentiation, and signal transduction. The study confirmed the existence of BTZ-induced complex epigenetic alterations in nerve cells. However, further studies are necessary to assess the reversibility of epigenetic changes and their potential impact on the induction/resolution of PN. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Adjuvant Lineage-Negative Cell Therapy as a Potential Silencer of the Complement-Mediated Immune System in ALS Patients.
- Author
-
Sobuś, Anna, Baumert, Bartłomiej, Gołąb-Janowska, Monika, Kulig, Piotr, Paczkowska, Edyta, Łuczkowska, Karolina, Rogińska, Dorota, Zawiślak, Alicja, Milczarek, Sławomir, Osękowska, Bogumiła, Pawlukowska, Wioletta, Meller, Agnieszka, Machowska-Sempruch, Karolina, Wełnicka, Agnieszka, Nowacki, Przemysław, and Machaliński, Bogusław
- Subjects
IMMUNE system ,CELLULAR therapy ,MOTOR neuron diseases ,COMPLEMENT (Immunology) ,COMPLEMENT activation ,ECULIZUMAB - Abstract
ALS remains a fatal, neurodegenerative motor neuron disease. Numerous studies seem to confirm that innate immune system is involved in the pathophysiology of ALS. Hence, the assessment of the complement system and attempts to modify its activity remain the target of medical intervention in ALS. In the present study, three intrathecal administrations of autologous bone marrow-derived lineage-negative (Lin
– ) cells were performed every 6 weeks in 20 sporadic ALS patients. The concentrations of various complement components in the cerebrospinal fluid and plasma at different time points after cell injection were quantified using a Luminex multiplex. The results of the complement system were correlated with the level of leukocytes, neutrophils, lymphocytes, fibrinogen and CRP in the peripheral blood and the functional status of ALS patients using Norris and ALS-FRSr scales. The study showed a statistically significant decrease in plasma C3b concentration in all 7th days after cell application. In parallel, a peak decrease in neutrophil count and CRP level was observed on days 5–7, with a simultaneous maximum clinical improvement on days 7–28 of each Lin– cell administration. Adjuvant Lin– cell therapy appears to have the silencing potential on the complement-mediated immune system and thus suppress pro-inflammatory reactions responsible for neurodegeneration. However, further in-depth studies are necessary to address this issue. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
40. The Potential Role of Proinflammatory Cytokines and Complement Components in the Development of Drug-Induced Neuropathy in Patients with Multiple Myeloma.
- Author
-
Łuczkowska, Karolina, Rutka, Magdalena, Rogińska, Dorota, Paczkowska, Edyta, Baumert, Bartłomiej, Milczarek, Sławomir, Górska, Martyna, Kulig, Piotr, Osękowska, Bogumiła, Janowski, Michał, Safranow, Krzysztof, Sommerfeld, Krzysztof, Borowiecka, Ewa, Zawodny, Piotr, Koclęga, Anna, Helbig, Grzegorz, and Machaliński, Bogusław
- Subjects
- *
COMPLEMENT (Immunology) , *MULTIPLE myeloma , *DRUG side effects , *GENE expression , *MICROARRAY technology - Abstract
The launch of novel chemotherapeutic agents—in particular, proteasome inhibitors and immunomodulatory drugs—dramatically changed multiple myeloma (MM) therapy, improving the response rate and prolonging progression-free survival. However, none of the anti-MM drugs are deprived of side effects. Peripheral neuropathy (PN) seems to be one of the most pressing problems. Despite extensive research in this area, the pathogenesis of drug-induced peripheral neuropathy (DiPN) has not yet been fully elucidated. In the present study, we aimed to assess the potential relationship between proinflammatory factors and the development of PN in MM patients with particular emphasis on the application of VTD (bortezomib, thalidomide, dexamethasone) regimen. Our analysis identified increased concentrations of CCL2, IL-1β, and IFN-γ in plasma of MM patients during treatment, both with and without symptoms of PN, compared with untreated neuropathy-free MM patients. At the same time, the plasma concentration of IL-1β in patients with neuropathy was significantly increased compared with patients without PN before and during treatment. Moreover, the results were enhanced at the transcript level by performing global mRNA expression analysis using microarray technology. The most significant changes were observed in the expression of genes responsible for regulating immunological and apoptotic processes. An in-depth understanding of the mechanisms responsible for the development of DiPN might in the future reduce the incidence of PN and accelerate diagnosis, allowing the choice of neuropathy-free treatment strategies for MM. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. The Clinical Importance of IL-6, IL-8, and TNF-α in Patients with Ovarian Carcinoma and Benign Cystic Lesions.
- Author
-
Pawlik, Weronika, Pawlik, Jakub, Kozłowski, Mateusz, Łuczkowska, Karolina, Kwiatkowski, Sebastian, Kwiatkowska, Ewa, Machaliński, Bogusław, and Cymbaluk-Płoska, Aneta
- Subjects
OVARIAN cancer ,INTERLEUKIN-6 ,SENSITIVITY & specificity (Statistics) ,MANN Whitney U Test ,TUMOR necrosis factors ,CANCER diagnosis - Abstract
The exact pathogenesis and influence of various cytokines in patients with ovarian lesions remains unclear. Hence, this study aimed to investigate whether IL-6, IL-8, and TNF-α could be considered as new useful markers for diagnosis of ovarian cancer. 63 women diagnosed with ovarian cancer (OC) and 53 patients with benign ovarian cystic (BOC) lesions were included in this study. Serum levels of IL-6, IL-8, and TNF-α were measured using ELISA. Statistical comparisons were made using the Mann–Whitney U test and all correlations were evaluated by Spearman's ranks. The serum IL-8 and TNF-α concentration measured in the OC Group was significantly higher than in the BOC Group (p < 0.05). The cutoff level of IL-8 and TNF-α in the serum was set at 4.09 ng/mL and 2.63 ng/mL, respectively, with the sensitivity and specificity of 70% and 96% for IL-8 and 85.7% and 79.3% for TNF-α (p < 0.0001). These results suggest that IL-8 and TNF-α are useful biomarkers for predicting the malignant character of lesions of the ovary. The present study highlighted the importance of measuring the cytokines such as IL-8 and TNF-α in patients with ovarian lesions in predicting the clinical outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
42. Repeated Application of Autologous Bone Marrow-Derived Lineage-Negative Stem/Progenitor Cells—Focus on Immunological Pathways in Patients with ALS.
- Author
-
Baumert, Bartłomiej, Sobuś, Anna, Gołąb-Janowska, Monika, Paczkowska, Edyta, Łuczkowska, Karolina, Rogińska, Dorota, Zawiślak, Alicja, Milczarek, Sławomir, Osękowska, Bogumiła, Pawlukowska, Wioletta, Meller, Agnieszka, Machowska-Sempruch, Karolina, Wełnicka, Agnieszka, Safranow, Krzysztof, Nowacki, Przemysław, and Machaliński, Bogusław
- Subjects
PROGENITOR cells ,MOTOR neuron diseases ,BONES ,AMYOTROPHIC lateral sclerosis ,GENE expression profiling ,CEREBROSPINAL fluid examination ,PROTEIN expression ,STEM cell treatment - Abstract
Therapeutic interventions in amyotrophic lateral sclerosis (ALS) are still far from satisfying. Immune modulating procedures raise hopes for slowing the disease progression. Stem cell therapies are believed to possess the ability to regulate innate and adaptive immune response and inflammation processes. Hence, three intrathecal administrations of autologous bone marrow-derived lineage-negative (Lin
– ) cells were performed every six weeks in 40 sporadic ALS patients. The concentrations of inflammatory-related proteins and expression profiles of selected miRNA in the cerebrospinal fluid (CSF) and plasma at different timepoints post-transplantation were quantified by multiplex Luminex and qRT-PCR. The global gene expression in nucleated blood cells was assessed using the gene microarray technique. According to the ALS Functional Rating Scale (FRSr), the study population was divided into responders (group I, n = 17) and non-responders (group II, n = 23). A thorough analysis of the pro-inflammatory expression profiles, regulated miRNA pathways, and global gene expression profiles at the RNA level revealed the local and systemic effects of Lin– cell therapy on the immune system of patients with ALS. The autologous application of Lin– cells in CSF modulates immune processes and might prevent the progression of neurodegeneration. However, further in-depth studies are necessary to confirm the findings, and prolonged intervention is needed to maintain therapeutic effects. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
43. Differential Secretion of Angiopoietic Factors and Expression of MicroRNA in Umbilical Cord Blood from Healthy Appropriate-For-Gestational-Age Preterm and Term Newborns—in Search of Biomarkers of Angiogenesis-Related Processes in Preterm Birth.
- Author
-
Gródecka-Szwajkiewicz, Dorota, Ulańczyk, Zofia, Zagrodnik, Edyta, Łuczkowska, Karolina, Rogińska, Dorota, Kawa, Miłosz P., Stecewicz, Iwona, Safranow, Krzysztof, and Machaliński, Bogusław
- Subjects
CORD blood ,PREMATURE labor ,SECRETION ,CHILDBIRTH ,MICRORNA ,PREMATURE infants - Abstract
Objectives: Premature birth, defined as less than 37 weeks gestation, affects approximately 12% of all live births around the world. Advances in neonatal care have resulted in the increased survival of infants born prematurely. Although prematurity is a known risk factor for different cardiovascular diseases, little is known about the pathophysiology of vasculature during premature gestation and angiopoietic factors network during premature birth. Aims: The objective of this study was to determine whether the profile of several pro-angiogenic and anti-angiogenic factors in umbilical cord blood (UCB) is different in healthy appropriate-for-gestational-age preterm newborns and normal term babies. The second aim of this study was to investigate the microRNA (miRNAs) expression profile in UCB from preterm labor and to detect miRNAs potentially taking part in control of angogenesis-related processes (Angio-MiRs). Methods: Using an immunobead Luminex assay, we simultaneously measured the concentration of Angiogenin, Angiopoietin-1, FGF-acidic, FGF-basic, PDGF-aa, PlGF, VEGF, VEGF-D, Endostatin, Thrombospondin-2, NGF, BDNF, GDNF, and NT-4 in UCB samples collected from the preterm (n = 27) and term (n = 52) delivery. In addition, the global microRNA expression in peripheral blood mononuclear cells (PBMCs) circulating in such UCB samples was examined in this study using microarray MiRNA technique. Results: The concentrations of five from eight measured pro-angiogenic factors (VEGF, Angiopoietin-1, PDGF-AA, FGF-a, and FGF-b) were significantly lower in UCB from preterm newborns. On the contrary, two angiostatic factors (Endostatin and Thrombospondin-2) were significantly up-regulated in preterm UCB. Among analyzed neurotrophins in preterm newborns, the elevated UCB concentration was found only in the case of GDNF, whereas BDNF was significantly reduced. Moreover, two angiopoietic factors, VEGF-D and PlGF, and two neurotrophins, NT4 and NGF, did not differ in concentration in preterm and term babies. We also discovered that among the significantly down-regulated miRNAs, there were several classical Angio-MiRs (inter alia MiR-125, MiR-126, MiR-145, MiR-150, or MiR155), which are involved in angiogenesis regulation in newborn after preterm delivery. Conclusions: This is the first report of simultaneous measurements of several angiopoietic factors in UCB collected from infants during preterm and term labor. Here, we observed that several pro-angiogenic factors were at lower concentration in UCB collected from preterm newborns than term babies. In contrast, the two measured angiostatic factors, Endostatin and Thrombospondin-2, were significantly higher in UCB from preterm babies. This can suggest that distinct pathophysiological contributions from differentially expressed various angiopoietic factors may determine the clinical outcomes after preterm birth. Especially, our angiogenesis-related molecules analysis indicates that preterm birth of healthy, appropriate-for-gestational-age newborns is an "anti-angiogenic state" that may provide an increased risk for improper development and function of cardiovascular system in the adulthood. This work also contributes to a better understanding of the role of miRNAs potentially involved in angiogenesis control in preterm newborns. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
44. Effect of Bortezomib on Global Gene Expression in PC12-Derived Nerve Cells.
- Author
-
Łuczkowska, Karolina, Rogińska, Dorota, Ulańczyk, Zofia, and Machaliński, Bogusław
- Subjects
- *
NEURONS , *GENE expression , *CELL cycle regulation , *BORTEZOMIB , *CELLULAR control mechanisms - Abstract
Peripheral neuropathy is one of the main side-effects of novel therapeutics used in oncohematological diseases, but the molecular basis underlying its development and progression as well as neurotoxicity mechanisms induced by the use of these therapeutics are still not fully elucidated. The aim of this study was to demonstrate the effect of bortezomib on global gene and miRNA expression on PC12-derived nerve cells. Microarray analysis showed that expression of 1383 genes was downregulated at least two fold and 671 genes were upregulated at least two fold in PC12-derived nerve cells treated with bortezomib compared to untreated/control cells. Analysis of functional annotations mainly identified downregulated processes (e.g., regulation of cell cycle, DNA replication and repair, regulation of cell migration, neuron projection morphogenesis and neurotransmitter secretion). The result of miRNA expression analysis demonstrated only 11 significantly downregulated miRNAs (at least two fold) in bortezomib-treated PC12-derived nerve cells vs. control cells. MiRNAs regulate gene expression, therefore we decided to conduct an analysis comparing the outcomes of miRNA microarray expression data to the obtained mRNA data. The most interesting miRNA–target gene correlation is downregulated expression of miR-130a-3p and miR-152-3p and as a result of this downregulation the expression of the Gadd45 increased. This gene is a member of a group of genes, the transcript expression of which is enhanced after stressful growth arrest conditions and treatment with DNA-damaging agents like drugs or mutagens. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
45. Local and Systemic Humoral Response to Autologous Lineage-Negative Cells Intrathecal Administration in ALS Patients.
- Author
-
Baumert, Bartłomiej, Sobuś, Anna, Gołąb-Janowska, Monika, Ulańczyk, Zofia, Paczkowska, Edyta, Łuczkowska, Karolina, Zawiślak, Alicja, Milczarek, Sławomir, Osękowska, Bogumiła, Meller, Agnieszka, Machowska-Sempruch, Karolina, Wełnicka, Agnieszka, Safranow, Krzysztof, Nowacki, Przemysław, and Machaliński, Bogusław
- Subjects
BRAIN-derived neurotrophic factor ,AMYOTROPHIC lateral sclerosis ,NEUROTROPHIN receptors ,PATHOLOGY ,PROGENITOR cells ,CEREBROSPINAL fluid ,C-reactive protein ,NEUROTROPHINS - Abstract
Amyotrophic lateral sclerosis (ALS) remains a fatal disease with limited therapeutic options. Signaling via neurotrophins (NTs), neuroinflammation, and certain micro-RNAs are believed to play essential role in ALS pathogenesis. Lineage-negative stem/progenitor cells (Lin
− ) were obtained from bone marrow of 18 ALS patients and administered intrathecally. Clinical assessment was performed using ALS Functional Rating Scale (FRSr) and Norris scale. Protein concentrations were measured in plasma and cerebrospinal fluid (CSF) by multiplex fluorescent bead-based immunoassay. Gene expression in nucleated blood cells was assessed using gene microarray technique. Finally, miRNA expression was analyzed using qPCR in CSF and plasma samples. We observed a significant decrease of C-reactive protein (CRP) concentration in plasma on the seventh day from the application of cells. Gene array results revealed decreased expression of gene sets responsible for neutrophil activation. Further analysis revealed moderate negative correlation between CRP level in CSF and clinical outcome. Brain-derived neurotrophic factor (BDNF) concentrations in both plasma and CSF significantly correlated with the favorable clinical outcome. On a micro-RNA level, we observed significant increase of miR-16-5p expression one week after transplantation in both body fluids and significant increase of miR-206 expression in plasma. Administration of Lin− cells may decrease inflammatory response and prevent neurodegeneration. However, these issues require further investigations. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
46. Molecular Mechanisms of Bortezomib Action: Novel Evidence for the miRNA–mRNA Interaction Involvement.
- Author
-
Łuczkowska, Karolina, Rogińska, Dorota, Ulańczyk, Zofia, Paczkowska, Edyta, Schmidt, Christian Andreas, and Machaliński, Bogusław
- Subjects
- *
RNA interference , *BIOCHEMICAL mechanism of action , *INTRACELLULAR calcium , *GENE expression profiling , *MICROARRAY technology , *NEUROTOXICOLOGY - Abstract
Bortezomib is an anti-tumor agent, which inhibits 26S proteasome degrading ubiquitinated proteins. While apoptotic transcription-associated activation in response to bortezomib has been suggested, mechanisms related to its influence on post-transcriptional gene silencing mediated regulation by non-coding RNAs remain not fully elucidated. In the present study, we examined changes in global gene and miRNA expression and analyzed the identified miRNA–mRNA interactions after bortezomib exposure in human neuroblastoma cells to define pathways affected by this agent in this type of cells. Cell viability assays were performed to assess cytotoxicity of bortezomib. Global gene and miRNA expression profiles of neuroblastoma cells after 24-h incubation with bortezomib were determined using genome-wide RNA and miRNA microarray technology. Obtained results were then confirmed by qRT-PCR and Western blot. Further bioinformatical analysis was performed to identify affected biological processes and pathways. In total, 719 genes and 28 miRNAs were downregulated, and 319 genes and 61 miRNAs were upregulated in neuroblastoma cells treated with bortezomib. Possible interactions between dysregulated miRNA/mRNA, which could be linked to bortezomib-induced neurotoxicity, affect neurogenesis, cellular calcium transport, and neuron death. Bortezomib might exert toxic effects on neuroblastoma cells and regulate miRNA–mRNA interactions influencing vital cellular functions. Further studies on the role of specific miRNA–mRNA interactions are needed to elucidate mechanisms of bortezomib action. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
47. Associations of MicroRNAs, Angiogenesis-Regulating Factors and CFH Y402H Polymorphism—An Attempt to Search for Systemic Biomarkers in Age-Related Macular Degeneration.
- Author
-
Ulańczyk, Zofia, Sobuś, Anna, Łuczkowska, Karolina, Grabowicz, Aleksandra, Mozolewska-Piotrowska, Katarzyna, Safranow, Krzysztof, Kawa, Miłosz Piotr, Pałucha, Andrzej, Krawczyk, Mariusz, Sikora, Piotr, Matczyńska, Ewa, Machaliński, Bogusław, and Machalińska, Anna
- Subjects
RETINAL degeneration ,GROWTH factors ,NEOVASCULARIZATION ,OLDER people ,BLOOD plasma ,RETROLENTAL fibroplasia ,BIOLOGICAL tags - Abstract
Age-related macular degeneration (AMD) remains the leading cause of blindness in elderly people, but the pathophysiology of this disease is still largely unknown. We investigated the systemic expression of angiogenesis-regulating growth factors and selected miRNAs known to regulate angiogenesis in AMD patients. We also focused on possible correlations of their expression with the presence of CFH Y402H or ARMS A69S risk variants. A total of 354 AMD patients and 121 controls were enrolled in this study. The levels of angiogenesis-regulating factors were analyzed in plasma samples using Luminex technology. The expression of selected miRNAs was analyzed in peripheral blood plasma using real-time qPCR. The genetic analysis was performed with an Illumina NextSeq500 system. AMD was an independent factor associated with lower levels of angiogenin (β = −0.29, p < 0.001), endostatin (β = −0.18, p < 0.001), FGF-basic (β = −0.18, p < 0.001), PlGF (β = −0.24, p < 0.001), miRNA-21-3p (β = −0.13, p = 0.01) and miRNA-155-5p (β = −0.16, p = 0.002); and with higher levels of FGF-acidic (β = 0.11, p = 0.03), miRNA-23a-3p (β = 0.17, p < 0.001), miRNA-126-5p (β = 0.13, p = 0.009), miRNA-16-5p (β = 0.40, p < 0.001), miRNA-17-3p (β = 0.13, p = 0.01), miRNA-17-5p (β = 0.17, p < 0.001), miRNA-223-3p (β = 0.15, p = 0.004), and miRNA-93 (β = 0.11, p = 0.04). The expression of analyzed miRNA molecules significantly correlated with the levels of tested angiogenesis-regulating factors and clinical parameters in AMD patients, whereas such correlations were not observed in controls. We also found an association between the CFH Y402H polymorphism and miRNA profiles, whereby TT homozygotes showed evidently higher expression of miRNA-16-5p than CC homozygotes or TC heterozygotes (p = 0.0007). Our results suggest that the balance between systemic pro- and anti-angiogenic factors and miRNAs is vital in multifactorial AMD pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
48. Preclinical Evaluation of Long-Term Neuroprotective Effects of BDNF-Engineered Mesenchymal Stromal Cells as Intravitreal Therapy for Chronic Retinal Degeneration in Rd6 Mutant Mice.
- Author
-
Lejkowska, Renata, Kawa, Miłosz Piotr, Pius-Sadowska, Ewa, Rogińska, Dorota, Łuczkowska, Karolina, Machaliński, Bogusław, and Machalińska, Anna
- Subjects
RETINAL degeneration ,MESENCHYMAL stem cells ,BONE marrow ,REGENERATIVE medicine ,NEUROPROTECTIVE agents ,GENE expression - Abstract
This study aimed to investigate whether the transplantation of genetically engineered bone marrow-derived mesenchymal stromal cells (MSCs) to overexpress brain-derived neurotrophic factor (BDNF) could rescue the chronic degenerative process of slow retinal degeneration in the rd6 (retinal degeneration 6) mouse model and sought to identify the potential underlying mechanisms. Rd6 mice were subjected to the intravitreal injection of lentivirally modified MSC-BDNF or unmodified MSC or saline. In vivo morphology, electrophysiological retinal function (ERG), and the expression of apoptosis-related genes, as well as BDNF and its receptor (TrkB), were assessed in retinas collected at 28 days and three months after transplantation. We observed that cells survived for at least three months after transplantation. MSC-BDNF preferentially integrated into the outer retinal layers and considerably rescued damaged retinal cells, as evaluated by ERG and immunofluorescence staining. Additionally, compared with controls, the therapy with MSC-BDNF was associated with the induction of molecular changes related to anti-apoptotic signaling. In conclusion, BDNF overexpression observed in retinas after MSC-BDNF treatment could enhance the neuroprotective properties of transplanted autologous MSCs alone in the chronically degenerated retina. This research provides evidence for the long-term efficacy of genetically-modified MSC and may represent a strategy for treating various forms of degenerative retinopathies in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
49. Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib.
- Author
-
Łuczkowska K, Kulig P, Baumert B, and Machaliński B
- Subjects
- Humans, Bortezomib pharmacology, Vitamins, Vitamin K, DNA Methylation, Dietary Supplements, Vitamin D pharmacology, Multiple Myeloma drug therapy, Multiple Myeloma genetics
- Abstract
Multiple myeloma (MM) is a plasma cell malignancy that, despite recent advances in therapy, continues to pose a major challenge to hematologists. Currently, different classes of drugs are applied to treat MM, among others, proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. Most of them participate in an interplay with the immune system, hijacking its effector functions and redirecting them to anti-MM activity. Therefore, adjuvant therapies boosting the immune system may be potentially beneficial in MM therapy. Vitamin D (VD) and vitamin K (VK) have multiple so called "non-classical" actions. They exhibit various anti-inflammatory and anti-cancer properties. In this paper, we investigated the influence of VD and VK on epigenetic alterations associated with the proliferative potential of MM cells and the development of BTZ resistance. Our results showed that the development of BTZ resistance is associated with a global decrease in DNA methylation. On the contrary, both control MM cells and BTZ-resistant MM cells exposed to VD alone and to the combination of VD and VK exhibit a global increase in methylation. In conclusion, VD and VK in vitro have the potential to induce epigenetic changes that reduce the proliferative potential of plasma cells and may at least partially prevent the development of resistance to BTZ. However, further ex vivo and in vivo studies are needed to confirm the results and introduce new supplementation recommendations as part of adjuvant therapy.
- Published
- 2023
- Full Text
- View/download PDF
50. Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action.
- Author
-
Kulig P, Łuczkowska K, Bakinowska E, Baumert B, and Machaliński B
- Abstract
Bortezomib (BTZ) is widely implemented in the treatment of multiple myeloma (MM). Its main mechanism of action is very well established. BTZ selectively and reversibly inhibits the 26S proteasome. More precisely, it interacts with the chymotryptic site of the 20S proteasome and therefore inhibits the degradation of proteins. This results in the intracellular accumulation of misfolded or otherwise defective proteins leading to growth inhibition and apoptosis. As well as interfering with the ubiquitin-proteasome complex, BTZ elicits various epigenetic alterations which contribute to its cytotoxic effects as well as to the development of BTZ resistance. In this review, we summarized the epigenetic alterations elicited by BTZ. We focused on modifications contributing to the mechanism of action, those mediating drug-resistance development, and epigenetic changes promoting the occurrence of peripheral neuropathy. In addition, there are therapeutic strategies which are specifically designed to target epigenetic changes. Herein, we also reviewed epigenetic agents which might enhance BTZ-related cytotoxicity or restore the sensitivity to BTZ of resistant clones. Finally, we highlighted putative future perspectives regarding the role of targeting epigenetic changes in patients exposed to BTZ.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.